Skip to content
DataLookout
Menu

NCT07830303

Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Sep 2026 to Dec 2026
  2. Minor Secondary endpoints: 9 to 15
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percent Improvement From Baseline in Sleep Efficiency at Day 30
Timeframe: Baseline and Day 30

Secondary (15)

Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Score at Day 30
Change From Baseline in Polysomnography-Measured Sleep Latency at Day 30
Change From Baseline in Total Sleep Time at Day 30
Change From Baseline in Slow-Wave Sleep Percentage at Day 30
Change From Baseline in Rapid Eye Movement Sleep Percentage at Day 30
Show 10 moreShow less
Change From Baseline in Microarousal Frequency at Day 30
Change From Baseline in Psychometric Hepatic Encephalopathy Score During Treatment
Change From Baseline in Stroop EncephalApp Performance at Day 30
Change From Baseline in Epworth Sleepiness Scale Total Score at Day 30
Proportion of Participants With Reversal of Minimal Hepatic Encephalopathy by Day 30
Proportion of Participants With New-Onset Minimal Hepatic Encephalopathy Through Day 30
Incidence of Overt Hepatic Encephalopathy by Day 30
Proportion of Participants With Adverse Events
Proportion of Participants With Serious Adverse Events
Proportion of Participants Discontinuing Study Treatment Due to Adverse Events

Arms and interventions

DaridorexantExperimental

Participants will receive oral daridorexant once nightly for 30 days. The dose will be 25 mg or 50 mg according to liver function and the study protocol. For participants with Child-Pugh class B liver function, the dose will not exceed 25 mg per night.

PlaceboPlacebo comparator

Participants will receive matching placebo orally for 30 days.

Drugs: Daridorexant, Placebo

Sites

3 sites in 1 country